XBiotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	115.46	125.55	172.68	200.02	157.31	236.98
Short-Term Investments	-	-	-	-	60.17	-
Cash & Short-Term Investments	115.46	125.55	172.68	200.02	217.48	236.98
Cash Growth	-25.94%	-27.29%	-13.67%	-8.03%	-8.23%	-0.16%
Other Receivables	0.3	0.36	0.86	0.94	1.76	8.95
Total Trade Receivables	0.3	0.36	0.86	0.94	1.76	8.95
Other Current Assets	1.29	1.04	1.03	0.76	0.6	0.93
Total Current Assets	117.05	126.95	174.57	201.72	219.84	246.87
Net Property, Plant & Equipment	22.79	23.13	24.53	24.9	26.26	28.31
Total Assets	139.84	150.08	199.09	226.62	246.1	275.18
Accounts Payable	0.86	1.54	2.22	2.52	2.41	2.07
Accrued Expenses	2.04	6.32	2.63	3.5	1.6	1.37
Short-Term Debt	-	-	10.25	-	-	-
Other Current Liabilities	0.11	0.08	-	0.08	0.06	0.01
Total Current Liabilities	3	7.93	15.11	6.1	4.07	3.45
Other Long-Term Liabilities	1.82	1.8	1.72	1.67	1.64	2.34
Total Long-Term Liabilities	1.82	1.8	1.72	1.67	1.64	2.34
Total Liabilities	4.82	9.73	16.83	7.77	5.7	5.79
Common Stock	276.9	276.73	273.11	271.15	267.33	262.26
Accumulated Other Comprehensive Income	-	-	-	-	0.83	1.97
Retained Earnings	-141.88	-136.38	-90.84	-52.31	-27.75	5.15
Shareholders' Equity	135.02	140.35	182.27	218.85	240.4	269.39
Total Liabilities & Equity	139.84	150.08	199.09	226.62	246.1	275.18
Total Debt	-	0	10.25	0	0	0
Net Cash (Debt)	115.46	125.55	162.43	200.02	217.48	236.98
Net Cash Growth	-8.04%	-22.70%	-18.80%	-8.03%	-8.23%	-0.16%
Net Cash Per Share	3.79	4.12	5.33	6.57	5.72	7.89
Book Value	135.02	140.35	182.27	218.85	240.4	269.39
Book Value Per Share	4.43	4.60	5.98	7.19	6.33	8.97
Tangible Book Value	135.02	140.35	182.27	218.85	240.4	269.39
Tangible Book Value Per Share	4.43	4.60	5.98	7.19	6.33	8.97

SEC Filings: 10-K · 10-Q